CN108513547A - 用于epcam阳性膀胱癌的治疗方法 - Google Patents

用于epcam阳性膀胱癌的治疗方法 Download PDF

Info

Publication number
CN108513547A
CN108513547A CN201680027431.4A CN201680027431A CN108513547A CN 108513547 A CN108513547 A CN 108513547A CN 201680027431 A CN201680027431 A CN 201680027431A CN 108513547 A CN108513547 A CN 108513547A
Authority
CN
China
Prior art keywords
subject
immune conjugate
bladder
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680027431.4A
Other languages
English (en)
Chinese (zh)
Inventor
S·哈利
G·麦克唐纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viventia Bio Inc
Original Assignee
Viventia Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viventia Bio Inc filed Critical Viventia Bio Inc
Publication of CN108513547A publication Critical patent/CN108513547A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201680027431.4A 2015-03-12 2016-03-11 用于epcam阳性膀胱癌的治疗方法 Pending CN108513547A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562132246P 2015-03-12 2015-03-12
US62/132,246 2015-03-12
US201562267385P 2015-12-15 2015-12-15
US62/267,385 2015-12-15
PCT/US2016/022077 WO2016145349A1 (en) 2015-03-12 2016-03-11 Methods of treatment for epcam positive bladder cancer

Publications (1)

Publication Number Publication Date
CN108513547A true CN108513547A (zh) 2018-09-07

Family

ID=56879840

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680027431.4A Pending CN108513547A (zh) 2015-03-12 2016-03-11 用于epcam阳性膀胱癌的治疗方法

Country Status (8)

Country Link
US (1) US10576163B2 (enExample)
EP (1) EP3268040A4 (enExample)
JP (1) JP6824183B2 (enExample)
CN (1) CN108513547A (enExample)
AU (1) AU2016228755B2 (enExample)
CA (1) CA2979394A1 (enExample)
HK (1) HK1249020A1 (enExample)
WO (1) WO2016145349A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6824183B2 (ja) 2015-03-12 2021-02-03 セセン バイオ，インコーポレイテッド Ｅｐｃａｍ陽性膀胱癌の処置方法
AU2016228760B2 (en) 2015-03-12 2020-07-16 Viventia Bio Inc. Dosing strategies for targeting EPCAM positive bladder cancer
AU2016257722B2 (en) * 2015-05-01 2022-05-19 Baylor College Of Medicine Methods for enhancing an immune response with a CTLA-4 antagonist
TWI897855B (zh) * 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
CN110804643B (zh) * 2019-10-29 2022-06-21 同济大学 一种体外评价卡介苗对中性粒细胞活性影响的方法
WO2023141236A2 (en) * 2022-01-19 2023-07-27 Istari Oncology, Inc. Methods for treating bladder cancers by intravesical instillation of a chimeric poliovirus

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1816352A (zh) * 2003-04-30 2006-08-09 苏黎世大学 使用一种免疫毒素治疗癌症的方法
US20090171317A1 (en) * 2006-03-10 2009-07-02 Ebrahim Versi Self-Catheterization Device To Administes Compounds To The Bladder
US20100215670A1 (en) * 2006-10-30 2010-08-26 Jeannick Cizeau Immunotoxin Fusions Comprising An Antibody Fragment and a Plant Toxin Linked by Protease Cleavable Linkers
US20110104062A1 (en) * 2008-02-07 2011-05-05 K. W. Michael Siu Biomarkers for Head-And-Neck Cancers and Precancers
CN103732259A (zh) * 2011-06-24 2014-04-16 森彻斯有限公司 细胞外靶向药物缀合物
WO2014166002A1 (en) * 2013-04-12 2014-10-16 Viventia Bio Inc. Compositions and methods for detection and treatment of hepatocellular carcinoma
WO2014201492A1 (en) * 2013-06-17 2014-12-24 Darren Raymond Shafren Methods for the treatment of bladder cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
IL98528A0 (en) 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
CA2295189C (en) 1997-06-06 2010-11-23 Tanox Pharma B.V. Type-1 ribosome-inactivating protein
ATE267215T1 (de) 1997-12-08 2004-06-15 Lexigen Pharm Corp Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
US6280742B1 (en) 1998-06-17 2001-08-28 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
WO2000061635A2 (en) 1999-04-09 2000-10-19 Universität Zürich Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
MXPA03009924A (es) 2001-05-03 2004-01-29 Merck Patent Gmbh Anticuerpo recombinante especifico de tumor y uso del mismo.
US20030148950A1 (en) 2001-10-09 2003-08-07 Li Xin Kringle domain 1 of human hepatocyte growth factor and uses therefor
JP2005507659A (ja) 2001-10-15 2005-03-24 イミューノメディクス、インコーポレイテッド 直接ターゲッティング結合タンパク質
US20040022726A1 (en) 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
SI21272A (sl) 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Sintetski gen za humani granulocitne kolonije stimulirajoči dejavnik za ekspresijo v E. coli
CA2424255A1 (en) 2003-03-26 2004-09-26 Claudio Di Paolo Immunotoxins
DK1737961T3 (da) 2004-03-19 2013-08-05 Merck Patent Gmbh Modificerede bouganin proteiner, cytotoxiner og fremgangsmåder og anvendelser deraf
NZ552476A (en) 2004-06-10 2009-09-25 Viventia Biotech Inc Tumor specific antibody
CA2684330A1 (en) 2007-04-19 2008-10-30 Viventia Biotech Inc. Optimized nucleotide sequences of vb6-845 for expression of recombinant proteins
WO2009039630A1 (en) 2007-09-27 2009-04-02 Viventia Biotech Inc. Optimized nucleic acid sequences for the expression of vb4-845
CA2756246A1 (en) 2009-04-08 2010-10-14 Heinz Faulstich Amatoxin-armed target-binding moieties for the treatment of cancer
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
WO2011116387A1 (en) 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
DK3052525T3 (da) 2013-10-02 2019-10-07 Viventia Bio Inc Anti-epcam-antistoffer og anvendelsesfremgangsmåder
JP6824183B2 (ja) 2015-03-12 2021-02-03 セセン バイオ，インコーポレイテッド Ｅｐｃａｍ陽性膀胱癌の処置方法
AU2016228760B2 (en) 2015-03-12 2020-07-16 Viventia Bio Inc. Dosing strategies for targeting EPCAM positive bladder cancer
WO2017040801A2 (en) 2015-09-02 2017-03-09 Viventia Bio Inc. Methods for making and using an immunoconjugate for the treatment of cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1816352A (zh) * 2003-04-30 2006-08-09 苏黎世大学 使用一种免疫毒素治疗癌症的方法
US20090171317A1 (en) * 2006-03-10 2009-07-02 Ebrahim Versi Self-Catheterization Device To Administes Compounds To The Bladder
US20100215670A1 (en) * 2006-10-30 2010-08-26 Jeannick Cizeau Immunotoxin Fusions Comprising An Antibody Fragment and a Plant Toxin Linked by Protease Cleavable Linkers
US20110104062A1 (en) * 2008-02-07 2011-05-05 K. W. Michael Siu Biomarkers for Head-And-Neck Cancers and Precancers
CN103732259A (zh) * 2011-06-24 2014-04-16 森彻斯有限公司 细胞外靶向药物缀合物
WO2014166002A1 (en) * 2013-04-12 2014-10-16 Viventia Bio Inc. Compositions and methods for detection and treatment of hepatocellular carcinoma
WO2014201492A1 (en) * 2013-06-17 2014-12-24 Darren Raymond Shafren Methods for the treatment of bladder cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLAUDIO DI PAOLO等: "A Recombinant Immunotoxin Derived from a Humanized Epithelial Cell Adhesion Molecule-specific Single-Chain Antibody Fragment Has Potent and Selective Antitumor Activity", 《CLINICAL CANCER RESEARCH 》 *
JAMES M. MCKIERNAN等: "Phase I Trial of Intravesical Docetaxel in the Management of Superficial Bladder Cancer Refractory to Standard Intravesical Therapy", 《JOURNAL OF CLINICAL ONCOLOGY》 *
MARK KOWALSKI等: "A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients", 《DRUG DESIGN, DEVELOPMENT AND THERAPY》 *
MARK KOWALSKI等: "A Phase II Study of Oportuzumab Monatox: An Immunotoxin Therapy for Patients with Noninvasive Urothelial Carcinoma In Situ Previously Treated with Bacillus Calmette-Guérin", 《JOURNAL OF UROLOGY》 *

Also Published As

Publication number Publication date
AU2016228755A1 (en) 2017-10-05
EP3268040A1 (en) 2018-01-17
CA2979394A1 (en) 2016-09-15
JP2018509423A (ja) 2018-04-05
US10576163B2 (en) 2020-03-03
JP6824183B2 (ja) 2021-02-03
EP3268040A4 (en) 2018-09-12
WO2016145349A1 (en) 2016-09-15
HK1249020A1 (zh) 2018-10-26
AU2016228755B2 (en) 2020-09-10
US20180104356A1 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
JP7455787B2 (ja) グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法
CN108513547A (zh) 用于epcam阳性膀胱癌的治疗方法
AU2016228760B2 (en) Dosing strategies for targeting EPCAM positive bladder cancer
EP2927322A1 (en) Tumor specific antibody
EP3052525B1 (en) Anti-epcam antibodies and methods of use
KR20190034686A (ko) 항체, 결합 단편 및 사용 방법
CN106177984A (zh) 抗‑间皮素免疫缀合物及其应用
CN106167526A (zh) Rspo结合剂和其应用
JP2006517109A (ja) アンフィレグリン抗体ならびに癌および乾癬を処置するためのその使用
JP2006517109A5 (enExample)
US20160060352A1 (en) Compositions and methods for detection and treatment of hepatocellular carcinoma
US20190284264A1 (en) Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
CN103717236A (zh) 治疗肺癌和前列腺癌的抗-cd22抗原结合分子
CN114729045B (zh) 对糖基化的ctla-4特异性的抗体及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180907